Literature DB >> 15756147

Natural history of hepatitis B.

P Marcellin1, C Castelnau, M Martinot-Peignoux, N Boyer.   

Abstract

The natural course of hepatitis B virus (HBV) chronic infection is variable, ranging from an inactive HBsAg carrier state to a more or less progressive chronic hepatitis, potentially evolving to cirrhosis and hepatocellular carcinoma (HCC). Chronic hepatitis may present as typical HBeAg-positive chronic hepatitis B or HBeAg-negative chronic hepatitis B. HBeAg-positive chronic hepatitis is due to wild type HBV; it represents the early phase of chronic HBV infection. HBeAg-negative chronic hepatitis is due to a naturally occurring HBV variant with mutations in the precore or/and basic core promoter regions of the genome; it represents a late phase of chronic HBV infection. The latter form of the disease has been recognized as increasing in many countries within the last decade and it represents the majority of cases in many countries. HBeAg-negative chronic hepatitis B is generally associated with a more severe liver disease with a very low rate of spontaneous disease remission and a low sustained response rate to antiviral therapy. Longitudinal studies of patients with chronic hepatitis B indicate that, after diagnosis, the 5-year cumulative incidence of developing cirrhosis ranges from 8-20%. Morbidity and mortality in chronic hepatitis B are linked to evolution to cirrhosis or HCC. The 5-year cumulative incidence of hepatic decompensation is approximately 20%. The 5-year probability of survival is approximately 80-86% in patients with compensated cirrhosis. Patients with decompensated cirrhosis have a poor prognosis (14-35% probability of survival at 5 years). HBV-related end-stage liver disease or HCC are responsible for at least 500,000 deaths per year.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15756147

Source DB:  PubMed          Journal:  Minerva Gastroenterol Dietol        ISSN: 1121-421X


  8 in total

1.  Cost-effectiveness analysis of prophylactic lamivudine use in preventing vertical transmission of hepatitis B virus infection.

Authors:  Hui-Fang Hung; Hsiu-Hsi Chen
Journal:  Pharmacoeconomics       Date:  2011-12       Impact factor: 4.981

Review 2.  Toward Elimination of Hepatitis B Virus Using Novel Drugs, Approaches, and Combined Modalities.

Authors:  Sebastien Boucle; Leda Bassit; Maryam Ehteshami; Raymond F Schinazi
Journal:  Clin Liver Dis       Date:  2016-08-30       Impact factor: 6.126

3.  Expertise of laboratories in viral load quantification, genotyping, and precore mutant determination for hepatitis B virus in a multicenter study.

Authors:  Syria Laperche; Vincent Thibault; Françoise Bouchardeau; Sophie Alain; Sandrine Castelain; Michelle Gassin; Marie Gueudin; Philippe Halfon; Sylvie Larrat; Françoise Lunel; Michèle Martinot-Peignoux; Bernard Mercier; Jean-Michel Pawlotsky; Bruno Pozzetto; Anne-Marie Roque-Afonso; Françoise Roudot-Thoraval; Karine Sauné; Jean-Jacques Lefrère
Journal:  J Clin Microbiol       Date:  2006-10       Impact factor: 5.948

4.  Economic evaluation of delivering hepatitis B vaccine to injection drug users.

Authors:  Yiqing Hu; Lauretta E Grau; Greg Scott; Karen H Seal; Patricia A Marshall; Merrill Singer; Robert Heimer
Journal:  Am J Prev Med       Date:  2008-07       Impact factor: 5.043

5.  Safety, Tolerability, and Pharmacokinetics of ARC-520 Injection, an RNA Interference-Based Therapeutic for the Treatment of Chronic Hepatitis B Virus Infection, in Healthy Volunteers.

Authors:  Thomas Schluep; Jason Lickliter; James Hamilton; David L Lewis; Ching-Lung Lai; Johnson Yn Lau; Stephen A Locarnini; Robert G Gish; Bruce D Given
Journal:  Clin Pharmacol Drug Dev       Date:  2016-12-12

Review 6.  Drugs in Development for Hepatitis B.

Authors:  Altaf Dawood; Syed Abdul Basit; Mahendran Jayaraj; Robert G Gish
Journal:  Drugs       Date:  2017-08       Impact factor: 9.546

7.  The Study of Correlation Between Serum Vitamin D3 Concentrations and HBV DNA Levels and Immune Response in Chronic Hepatitis Patients.

Authors:  Wang-Sheng Ko; Yen-Ping Yang; Fang-Ping Shen; Mu-Chen Wu; Chia-Ju Shih; Mei-Chun Lu; Yuan-Horng Yan; Ya-Ling Chiou
Journal:  Nutrients       Date:  2020-04-16       Impact factor: 5.717

8.  The 25(OH)Vitamin D Status Affected the Effectiveness of Oligo Fucoidan in Patients with Chronic Hepatitis B Virus Infection with Immune Tolerance Phase.

Authors:  Wang-Sheng Ko; Fang-Ping Shen; Chia-Ju Shih; Ya-Ling Chiou
Journal:  Nutrients       Date:  2020-01-26       Impact factor: 5.717

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.